Drug Discovery

Candidate Prioritization in Drug Discovery Under Multiple Objectives

Published 2026-08-22 · Updated 2026-08-22

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which candidate best balances potency, selectivity, exposure, safety, developability, and information value

Why the problem is difficult

The article-specific identification challenge is whether the question “which candidate best balances potency, selectivity, exposure, safety, developability, and information value” can be resolved using assay comparability, uncertainty, property tradeoffs, mechanism, off-targets, and route feasibility, rather than merely restated in new language.

A falsifier-first workflow

• Define the decision precisely: which candidate best balances potency, selectivity, exposure, safety, developability, and information value.
• Build a source and data ledger around assay comparability, uncertainty, property tradeoffs, mechanism, off-targets, and route feasibility.
• Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
• Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
• Run the lowest-cost discriminating challenge: perturb weights and assay normalization to test ranking stability.
• Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

• Decision impact: would the result materially change the choice about which candidate best balances potency, selectivity, exposure, safety, developability, and information value?
• Evidence fit: does the available evidence—assay comparability, uncertainty, property tradeoffs, mechanism, off-targets, and route feasibility—directly address the decision rather than merely correlate with it?
• Discrimination: does the preferred route predict an outcome a credible alternative does not?
• Robustness: does the ranking survive the challenge “perturb weights and assay normalization to test ranking stability”?
• Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

assay comparability, uncertainty, property tradeoffs, mechanism, off-targets, and route feasibility

Counterevidence

For this decision, a result from “perturb weights and assay normalization to test ranking stability” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which candidate best balances potency, selectivity, exposure, safety, developability, and information value or exposes why the available evidence cannot resolve it.

Fastest falsifier

perturb weights and assay normalization to test ranking stability

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “perturb weights and assay normalization to test ranking stability” without an independently supported alternative mechanism.

Evidence ceiling

Multi-parameter rankings depend on data quality and cannot replace integrated experimental judgment.

Sources and starting points

• Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
• ChEMBL — Curated bioactivity information for compounds, assays, and targets.
• ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
• PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
• Europe PMC — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
• PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

1. Drug Target Prioritization: A Falsifier-First Framework
2. Target Identification vs Target Validation in Drug Discovery
3. What Counts as Evidence for Drug Target Validation?
4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Candidate Prioritization in Drug Discovery Under Multiple Objectives” help make?

It supports a bounded decision about which candidate best balances potency, selectivity, exposure, safety, developability, and information value. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.

What is the fastest useful test?

perturb weights and assay normalization to test ranking stability

Can computation validate the final scientific claim?

No. Multi-parameter rankings depend on data quality and cannot replace integrated experimental judgment. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.